Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2153738
Max Phase: Preclinical
Molecular Formula: C37H36F3N4O7PS
Molecular Weight: 768.75
Molecule Type: Small molecule
Associated Items:
ID: ALA2153738
Max Phase: Preclinical
Molecular Formula: C37H36F3N4O7PS
Molecular Weight: 768.75
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CP(=O)(O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)Sc1ccccc1OC(F)(F)F
Standard InChI: InChI=1S/C37H36F3N4O7PS/c38-37(39,40)51-30-17-9-10-18-31(30)53-32(35(46)43-29(34(41)45)20-26-21-42-28-16-8-7-15-27(26)28)23-52(48,49)33(19-24-11-3-1-4-12-24)44-36(47)50-22-25-13-5-2-6-14-25/h1-18,21,29,32-33,42H,19-20,22-23H2,(H2,41,45)(H,43,46)(H,44,47)(H,48,49)/t29-,32+,33+/m0/s1
Standard InChI Key: CGPJRIXIBMANTN-PHCUSUGSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 768.75 | Molecular Weight (Monoisotopic): 768.1994 | AlogP: 6.51 | #Rotatable Bonds: 16 |
Polar Surface Area: 172.84 | Molecular Species: ACID | HBA: 7 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: 1.52 | CX Basic pKa: | CX LogP: 6.52 | CX LogD: 4.14 |
Aromatic Rings: 5 | Heavy Atoms: 53 | QED Weighted: 0.06 | Np Likeness Score: -0.44 |
1. Mucha A, Kafarski P, Berlicki Ł.. (2011) Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry., 54 (17): [PMID:21780776] [10.1021/jm200587f] |
Source(1):